Related Experiment Video
Updated: Aug 11, 2026
13:18
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
Published on: April 10, 2026
Engineering Advanced Nanomedicine Against Depression: From Treatment Challenges to Delivery Strategies
Mijia Zhang1,2, Enyao He1, Youlan Xiong1
1Drug Research Center of Integrated Traditional Chinese and Western Medicine & Department of Gynecology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.
Advanced Healthcare Materials
|August 10, 2026
Summary
Engineered nanomedicine offers advanced solutions for depression treatment challenges, improving drug delivery beyond the blood-brain barrier for faster, more targeted therapies.
Area of Science:
- Neuroscience
- Nanotechnology
- Pharmacology
Background:
- Depression is a significant global health issue with current treatments facing limitations.
- Existing antidepressant pharmacotherapy struggles with slow onset, poor brain specificity, and challenges delivering biologics.
- Overcoming the blood-brain barrier (BBB) is crucial but insufficient for addressing all depression treatment deficits.
Purpose of the Study:
- To critically review advanced nanoengineering strategies for targeted antidepressant delivery.
- To evaluate the translational potential of different nanomedicine platforms for depression.
- To provide a framework for guiding future clinical development of nanomedicine-based antidepressants.
Main Methods:
- Review of engineered nanomedicine strategies for crossing the blood-brain barrier (BBB).
- Evaluation of techniques like receptor-mediated transport and cell-mimetic carriers.
- Analysis of nanomedicine platforms based on their design precision and translational feasibility.
Main Results:
- Engineered nanomedicine presents a promising platform to overcome limitations of current antidepressant therapies.
- Advanced designs enable targeted modulation of depression-related neural circuits.
- Nanomedicine offers potential for rapid onset, precise intervention, and improved patient outcomes.
Conclusions:
- Nanomedicine can address specific pharmacotherapeutic shortcomings in depression treatment.
- Moving beyond generic BBB penetration strategies is key for next-generation antidepressants.
- Engineered nanomedicine holds significant promise for improving depression therapy and patient quality of life.
Keywords:
blood–brain barrier penetrationcell biomimeticdepressionengineered nanomedicinenasal–brain deliveryreceptor‐mediatedMore Related Videos
05:19Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
Published on: July 7, 2023
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:18Depression: Overview
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.